Companies › HELP Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Metabolic and endocrine, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HiCM-188 Allogeneic human induced pluripotent stem cell-derived cardiomyocytes | – | Phase 3 | Heart Failure | Nov 2026 |
| HMM910 Human umbilical cord-derived mesenchymal stem cells | – | Phase 1 | Osteoporosis in Post-menopausal Women | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06949137 | HMM910 | Phase 1 | Osteoporosis in Post-menopausal Women | Metabolic and endocrine | Mar 2026 |
| NCT06340048 | HiCM-188 | Phase 1 | Heart Failure | Cardiovascular | Nov 2026 |
| NCT07496372 | HiCM-188 | Phase 3 | Heart Failure | Cardiovascular | Jun 2027 |
No annotated target.
–
Sirius Therapeutics Crystalys Therapeutics Vincentage Pharma RECORDATI GROUP Shanghai Minwei Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.